Novartis stock rose 3.1% on October 27, 2026, after the Swiss pharmaceutical company raised its full-year core operating income outlook. The gain came as the pan-European Stoxx 600 index declined 0.34%.
Key Takeaways
- The higher core operating income outlook is a forecast, not a completed full-year result.
- Novartis shares rose while the broader European index fell.
Novartis stock moves after outlook revision
The gain in Novartis’s NYSE-traded American depositary receipts followed the company’s upward revision to its full-year 2026 core operating income forecast. The available information does not specify the size of the revision or establish that it caused the share-price move.
The stock was quoted at $153.81. The quotation was not identified as a closing price, and its precise observation time was not specified.
European market comparison
The Stoxx 600’s decline contrasted with the gain in Novartis shares. The two figures refer to different instruments: one is an individual company’s U.S.-traded security, while the other is a broad European stock index.
Novartis focuses on prescription medicines. Its products include cardiovascular drug Entresto and cancer treatments Kisqali and Pluvicto.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…